000			05121nam a22003855i 4500
001			233991
003			ES-VaUE
005			20221220020534.0
007			cr nn 008mamaa
008			100301s2006 xxu| s |||| 0|eng d
020			_a9781597450171
024	7		_a10.1385/1597450170 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aMyeloid Leukemia _bMethods and Protocols _cedited by Harry Iland, Mark Hertzberg, Paula Marlton.
250			_a1st edition 2006
264		1	_aTotowa, NJ _bHumana Press _c2006
300			_a1 recurso en línea (320 páginas) _b69 ilustraciones
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Medicine _x1940-6037 _v125
505	0		_aIsolation of RNA and DNA From Leukocytes and cDNA Synthesis -- Cytogenetic and FISH Techniques in Myeloid Malignancies -- Overview of Real-Time RT-PCR Strategies for Quantification of Gene Rearrangements in the Myeloid Malignancies -- Diagnosis and Monitoring of Chronic Myeloid Leukemia by Qualitative and Quantitative RT-PCR -- Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate -- Deletion of the Derivative Chromosome 9 in Chronic Myeloid Leukemia -- Diagnosis and Monitoring of PML-RARA-Positive Acute Promyelocytic Leukemia by Qualitative RT-PCR -- Diagnosis and Monitoring of PML-RAR?-Positive Acute Promyelocytic Leukemia by Quantitative RT-PCR -- Diagnosis and Monitoring of AML1-MTG8 (ETO)-Positive Acute Myeloid Leukemia by Qualitative and Real-Time Quantitative RT-PCR -- Diagnosis and Monitoring of CBFB-MYH11-Positive Acute Myeloid Leukemia by Qualitative and Quantitative RT-PCR -- Detection of the FIP1L1-PDGFRA Fusion in Idiopathic Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia -- FLT3 Mutations in Acute Myeloid Leukemia -- WT-1 Overexpression in Acute Myeloid Leukemia and Myelodysplastic Syndromes -- Classification of AML by DNA-Oligonucleotide Microarrays -- Classification of AML Using a Monoclonal Antibody Microarray -- Methods for the Detection of the JAK2 V617F Mutation in Human Myeloproliferative Disorders -- Overexpression of PRV-1 Gene in Polycythemia Rubra Vera and Essential Thrombocythemia -- Chimerism Analysis Following Nonmyeloablative Stem Cell Transplantation.
520			_aThe highly significant role that acquired genetic abnormalities play in the genesis, diagnosis, and management of hematological malignancies has become increasingly clear. Such abnormalities can serve as useful markers for initial diagnosis, accurate subclassification, and the evaluation of minimal residual disease, as well as providing critical targets for novel therapies. In Myeloid Leukemia: Methods and Protocols, a panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number of specific genetic abnormalities associated with the broad spectrum of myeloid malignancies. The methods range from those that are of immediate clinical relevance to the investigation and management of patients with myeloid malignancies, to those that relate to recently identified genetic abnormalities of potential clinical significance. Highlights include techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of AML by DNA-oligonucleotide microarrays, and detection of the V617F JAK2 mutation in myeloproliferative disorders. In addition to gene rearrangments, other prognostically relevant molecular lesions such as FLT3 mutations and WT-1 overexpression are covered. The protocols follow the successful Methods in Molecular Biology™ series format, each offering step-by-step laboratory instructions, an introduction outlining the principles behind the technique, lists of the necessary equipment and reagents, and tips on troubleshooting and avoiding known pitfalls. Clinically relevant and highly practical, Myeloid Leukemia: Methods and Protocols offers cytogeneticists, hematologists, and oncologists cutting-edge laboratory techniques that can be rapidly implemented for the investigation and management of patients with myeloid malignancies.
700	1		_aIland, Harry _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aHertzberg, Mark _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aMarlton, Paula _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9781607614562
776	0	8	_iPrinted edition: _z9781607614579
776	0	8	_iPrinted edition: _z9781588294852
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1597450170 _z(usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
988			_aSpringer_Protocols_2006
999			_c233991 _d233991